NTLA vs EDIT
NTLA and EDIT side by side — valuation & fundamentals (public data).
Key statistics
| Metric | NTLAINTELLIA THERAPEUTICS, INC. | EDITEditas Medicine, Inc. |
|---|---|---|
| Market cap | $1.50B | $258.47M |
| P/S | 22.2x | 6.4x |
| Revenue growth (YoY) | 16.9% | 25.4% |
| Earnings growth (YoY) | 20.5% | 32.5% |
| EBIT margin | -651.7% | -394.9% |
| ROE | -66.5% | -3631.1% |
| 1y total return | -6.2% | +8.0% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: NTLA frente a EDIT
| Métrica | NTLA | EDIT |
|---|---|---|
| Valor final | $4.9K | $880 |
| Retorno total | -51.3% | -91.2% |
| CAGR | -6.8% | -21.1% |
| Volatilidad | 78.4% | 83.5% |
| Sharpe | 0.25 | 0.07 |
| Sortino | 0.37 | 0.11 |
| Caída máxima | -96.5% | -98.9% |
Basado en 2574 días de negociación comunes, 2016-05-06 → 2026-08-03 · tasa libre de riesgo 3.91% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)